
Loading, please wait...

Loading, please wait...

A recent systematic review investigates the influence of psychedelics on cognitive functions such as empathy, memory, and attention. Researchers analyzed 32 placebo-controlled studies from 1990 to 2025 involving substances like LSD, DMT, and psilocybin. The findings suggest that these compounds modulate human psychology in distinct, often dose-dependent ways. While some cognitive domains show enhancement, others experience temporary impairment during acute phases.
Notably, psychedelics appear to enhance emotional empathy, which is the ability to share another person's feelings. However, the data indicates no significant change in cognitive empathy or the intellectual understanding of others' perspectives. Similarly, the impact on memory remains highly variable. Consequently, researchers found that results depended heavily on the specific memory task and the timing of the assessment. Some participants showed improved recall, whereas others experienced no change or slight deficits.
Furthermore, executive functions such as reaction time, attention, and inhibition showed dose-dependent impairments. Specifically, higher doses tended to slow down reaction speeds and reduce the ability to focus. In contrast, some studies found no negative effects on these domains at all. Additionally, many users showed impaired recognition of negative stimuli while under the acute influence of these drugs. This shift in emotional processing could explain some of the therapeutic potential noted in clinical psychiatry.
Overall, the evidence regarding cognitive flexibility remains mixed and requires further clarification. Most existing studies utilize small sample sizes, which limits the generalizability of the findings. Moreover, the unique subjective effects of psychedelics make it difficult to establish a truly reliable placebo. Future clinical trials must focus on larger cohorts and longitudinal assessments to understand the long-term impact of these substances on human cognition.
No, evidence suggests they primarily enhance emotional empathy, which involves feeling what others feel. They do not seem to significantly affect cognitive empathy, which is the intellectual understanding of another's thoughts.
Current research focuses on acute and post-acute effects. While dose-dependent impairments in attention and reaction time occur during the experience, there is no strong evidence in this review suggesting permanent cognitive decline in clinical settings.
Memory effects depend on the specific type of memory being tested (e.g., working memory vs. long-term recall) and the time elapsed since administration. The results vary across different psychedelic compounds and dosages.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Kase M et al. Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature. J Psychopharmacol. 2026 Feb 16. doi: 10.1177/02698811251412012. PMID: 41699449.
Olami A, Peled-Avron L. Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task. Sci Rep. 2024;14:24480. doi: 10.1038/s41598-024-74810-w.
Meshkat S et al. Impact of psilocybin on cognitive function: A systematic review. Psychiatry Clin Neurosci. 2024 Oct;78(10):612-628. doi: 10.1111/pcn.13701.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A systematic review of 32 placebo-controlled studies analyzes how LSD, DMT, and psilocybin affect memory, empathy, and executive tasks between 1990 and 2025...
8 months ago

Explore how novel oxygen-releasing PVA hydrogels prevent early post-transplant hypoxic damage in pancreatic beta cells, sustaining viability and insulin secretory function.
Today

Delhi is undergoing a major healthcare overhaul with enhanced Ayushman Bharat insurance up to ₹10 lakh, increased MBBS and PG medical training seats, expanded primary network mandirs, new tertiary neuro-ICUs, and public-private reproductive technology initiatives to build a resilient, preventative healthcare model.
Today

Aon forecasts India's healthcare inflation will ease to 10.1% in 2027 from 11.5% in 2026. Despite moderation, healthcare expenses continue to outpace general inflation, propelled by non-communicable diseases, advanced medical therapeutics, and expanding utilization patterns across diverse patient populations.
Today

Non-union fractures occur in 2-5% of cases, causing significant disability and cost. Conservative modalities such as LIPUS, PEMF, and focused ESWT offer non-surgical healing options for defects up to 5-10 mm when adequate mechanical stability exists without infection.
Today

A Brazilian birth cohort reveals significant sex-specific associations between preterm birth and adolescent adiposity, underscoring the urgent need for targeted long-term cardiometabolic surveillance and tailored clinical monitoring.
Today